Governance

S. Louise Phanstiel, Chair of the Board of Directors, has been a director of Myriad since September 2009, held several executive positions at Anthem, Inc., formerly WellPoint, Inc. from 1996 to 2007. She was President, Specialty Products which included behavioral health services; Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman; and Chief Accounting Officer, Controller and Chief Financial Officer for all WellPoint, Inc. subsidiaries. Previously, Ms. Phanstiel was a partner at the international services firm PricewaterhouseCoopers, LLP, formerly Coopers & Lybrand, LLP where she specialized in insurance. Ms. Phanstiel’s life science experience includes having previously served on the Board of Directors and Chair of the Audit Committees at publicly traded companies, Inveresk Research Group, Inc. and Verastem, Inc.

Paul Bisaro is an experienced global business leader with almost 30 years of pharmaceutical experience and has a track record of driving company growth through operational execution and corporate transformation. He has served as Chief Executive Officer as well as Executive Chairman of numerous companies including Watson Pharmaceuticals, Actavis plc, Allergan plc, Impax Laboratories and Amneal Pharmaceuticals. Mr. Bisaro also served as Chief Operations Officer and General Counsel of Barr Laboratories. In addition to his service on the Board of Myriad, Mr. Bisaro serves as Chairman of the Board of Mallinckrodt, PLC and is also currently on the Board of Zoetis, Inc. (NYSE:ZTS). Since 2014, Mr. Bisaro has been a Member of the Board of Visitors of the Catholic University of America’s Columbus School of Law. He also served as Chairman of the Board of the Generic Pharmaceutical Association (GPhA, now the Association of Accessible Medicines) in 2010 and 2011. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan (1983) and a Juris Doctor from Catholic University of America in Washington, D.C. (1989).

Mark S. Davis was appointed as a director of Myriad Genetics in December 2024. Mr. Davis is the Senior Relationship and Growth Advisor for Cross Country Consulting. Previously, he enjoyed a distinguished career at Deloitte & Touche LLP from 1985 until 2024, serving in senior roles including Audit Partner, National Managing Partner of Deloitte Private Enterprises, and Managing Partner of the Long Island office. In June 2024, Mr. Davis was appointed to the board of directors of Yext, Inc. (NYSE:YEXT), where he serves as a director and member of the audit committee. He is also a member of the advisory board of NYU-Winthrop Hospital, and the Board of Trustees at Adelphi University, where he serves on the finance and investment committee as well as the audit committee. He holds a B.B.A. from Adelphi University and is a certified public accountant.

Heiner Dreismann, Ph.D., joined the company in June 2010. Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.

Rashmi Kumar was named a Director of Myriad Genetics in September 2020. Currently, she serves as Senior Vice President and Chief Information Officer, Global IT, at Hewlett Packard Enterprise. Prior to that, she was SVP and CIO, U.S Pharmaceutical, at McKesson and served in senior leadership roles for large enterprises including Southern California Edison, Toyota, and Tata Steel. She earned a Bachelor’s degree in metallurgical engineering from Bihar Institute of Technology in Sindri, India and a M.B.A. from University of California, Irvine’s Paul Merage School of Business.

Lee N. Newcomer, M.D., board-certified medical oncologist, joined the company in September 2019. Most recently, he was Senior Vice President of Oncology and Genetics for UnitedHealthcare. Previously, he served as Chief Medical Officer and Senior Vice President of Health Policy and Strategy at UnitedHealth Group, and Chief Medical Officer at Vivius, Inc. Dr. Newcomer earned a M.D. from University of Nebraska College of Medicine, a M.H.A from University of Wisconsin-Madison and a B.A. from Nebraska Wesleyan.

Sam Raha has served as president and chief executive officer and member of the board of directors at Myriad Genetics since April 2025. He is guided by Myriad’s mission to advance health and well-being for all, by focusing on the needs of patients and the healthcare providers who serve them. He joined Myriad in December 2023 as chief operating officer and played an integral role in shaping Myriad’s long-term growth strategy, while delivering new perspectives and expertise to advance business initiatives, operational excellence, and profitability. Sam has more than 30 years of proven experience in the life sciences and diagnostics industry. Before joining Myriad, he was the president of Agilent’s Diagnostics and Genomics Group with overall responsibility for the Group’s strategy, innovation, and results. Prior to Agilent, he led marketing and product at Illumina, and before that was the VP and general manager of the TaqMan/qPCR business at Life Technologies. Sam earned his MBA from Santa Clara University and has an undergraduate degree in molecular and cell biology from the University of California, Berkeley.

Colleen F. Reitan joined the company in September 2019. Most recently, she served as President of Plan Operations for Healthcare Service Corporation (HCSC). Prior to that, she held several roles, including serving as the Executive Vice President and Chief Operating Officer of HCSC and President and Chief Operating Officer of Blue Cross & Blue Shield of Minnesota. She previously served on boards at Availity LLC, MEDecision, Inc. and Prime Therapeutics LLC. Reitan has a M.H.A. from the University of Minnesota and a B.A. in Urban Studies and Economics from Minnesota State University.

Daniel M. Skovronsky, M.D., Ph.D., joined the company as a Director in July 2020. Currently, he serves as Chief Science Officer and President of Lilly Research Laboratories at Eli Lilly and Company. Previously, he was Chief Executive Officer of Avid Radiopharmaceuticals Inc., a company he founded in 2004. Dr. Skovronsky earned his M.D. from the Perelman School of Medicine, University of Pennsylvania, his Ph.D. in neuroscience from University of Pennsylvania and a B.S. in molecular biophysics and biochemistry from Yale University.